Our findings demonstrated that the broader regions of activation identified in HER2‐low tumors align with the known heterogeneity of this subtype.[32, 33] The differential expression of key genes further underscores the biological divergence between HER2‐low and HER2‐positive tumors, particularly involving tumor proliferation, HER2 signaling activation, and immune regulation. Here, ERBB2 is linked to neoplasm.